Welcome to our dedicated page for Pluri news (Ticker: PLUR), a resource for investors and traders seeking the latest updates and insights on Pluri stock.
Pluri Inc (PLUR) pioneers transformative biotechnology solutions through its patented 3D cell expansion platform, driving innovations across regenerative medicine, immunotherapy, and sustainable food production. This dedicated news hub provides investors and industry professionals with timely updates on corporate developments, strategic partnerships, and technological breakthroughs.
Access essential updates including earnings announcements, regulatory milestones, and progress in key sectors such as cultivated meat production through subsidiary Ever After Foods. Track advancements in off-the-shelf cell therapies for medical applications and manufacturing collaborations through Pluri's CDMO division.
Our curated news collection serves as your primary source for understanding Pluri's multi-industry impact. Discover updates on clinical trial progress, foodtech innovations, and manufacturing expansions while maintaining awareness of market-moving developments. Bookmark this page for streamlined access to press releases and analysis-free corporate announcements directly from verified sources.
Pluri (Nasdaq: PLUR) has announced a strategic partnership with Wilk Technologies to create a medical food product derived from human breast milk for the elderly. This innovative product utilizes Pluri's 3D cell-expansion technology in combination with Wilk's cell-cultured milk components. The global elderly nutrition market, valued at $25.2 billion, is projected to reach $39.7 billion within the next decade. This collaboration aims to meet the unique nutritional needs of seniors, enhancing their quality of life while addressing age-related health concerns and chronic illnesses.
Pluri Inc. launched a novel immunotherapy platform for solid tumor cancer treatment utilizing placental MAIT cells, a unique type of immune cells with great potential. Pluri's proprietary technology overcomes challenges in expanding MAIT cells, offering advantages over conventional T cells. The global cancer immunotherapy market is projected to reach $275.11 billion by 2032. Renowned cancer researchers Dr. Prasad S. Adusumilli and Dr. Richard L. Kendall joined Pluri's Scientific Advisory Board to support this groundbreaking platform.
FAQ
What is the current stock price of Pluri (PLUR)?
What is the market cap of Pluri (PLUR)?
